|
All Business Categories
|
InterMune , Inc.
California, USA InterMune, Inc., is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. We market Actimmune® (interferon gamma... Genzyme Corporation Massachusetts, USA One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. This year marks the 25th an... Cephalon , Inc. Pennsylvania, USA Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic ... Tranzyme , Inc. Quebec, Canada Tranzyme Pharma is developing proprietary therapeutic candidates from its own medicinal chemistry platform to treat underserved diseases of the GI tract such as post-operative ileu... Gilead Sciences , Inc. California, USA Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advan... Washington, USA ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of potential proprieta... Celera Genomics Group MARYLAND, USA Celera Diagnostics compares genotype and/or gene expression profiles in samples from healthy and affected individuals to associate genetic and genomic markers with disease. To cost... Antisoma plc London, United Kingdom Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promisin... Panacos Pharmaceuticals , Inc. Massachusetts, USA Panacos is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human v... Curis , Inc. Massachusetts, USA Curis will be positioned to identify and successfully commercialize therapeutic opportunities derived from the human genome program , said Doros Platika , MD , president and chief ...
1
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[741]
[1463]
[2184]
Next
Last
|
